Immunotherapy of Prolactinoma with a T Helper 1 Activator Adjuvant and Autoantigens: A Case Report
- 1 January 2006
- journal article
- case report
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 13 (4), 205-208
- https://doi.org/10.1159/000100405
Abstract
To date, efforts to reliably manipulate the immune system to promote tumor regression in the brain have been disappointing. We report a unique experience of successful immunotherapy to treat a pituitary macroprolactinoma. A 31-year-old woman with an established history of pituitary macroprolactinoma who had undergone tumor resection followed by radiation was admitted to our clinic. The diagnosis had been made due to the patient's symptoms, a serum prolactin (PRL) level of 29,600 mIU/l, a brain MRI revealing a 23 x 19 x 18 mm pituitary mass and a positive PRL immunohistochemistry of the mass. Six months following surgery, she reexperienced headache, excessive sweating and a serum PRL concentration of 2,960 mIU/l despite receiving 30 mg/day bromocriptine. Brain MRI revealed a pituitary mass (3 x 6 x 8 mm) compatible with a pituitary adenoma. Twenty micrograms per milliliter of G2 (as a T helper 1 activator adjuvant) was inoculated intradermally once per week for 24 consecutive weeks (each injection contained 10 mug of G2). The autoantigens were inoculated at the same time with G2. After immunotherapy, serum PRL concentration decreased to 82 mIU/l, the patient's symptoms disappeared, skin thickness increased to normal and bromocriptine dosage was tapered to 20 mg per week. A follow-up brain MRI revealed almost complete disappearance of the tumor. The patient does not complain of any problems at 1-year follow-up. Activation of both nonspecific (natural killer cells) and specific (cytotoxic T lymphocytes) immunity in relation to the T helper 1 cytokine network is a promising strategy for the treatment of tumors of the central nervous system in humans, especially pituitary macroprolactinomas.This publication has 22 references indexed in Scilit:
- Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomasClinical Endocrinology, 2006
- Headache induced by dopamine agonists prescribed for prolactinoma: think SUNCT!International Journal of Clinical Practice, 2006
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- The Case for Initial Surgical Removal of Certain ProlactinomasJournal of Clinical Endocrinology & Metabolism, 1997
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cellsNature Medicine, 1996
- Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancerCancer, 1994
- Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing MiceScience, 1992
- Immunobiology of primary intracranial tumorsJournal of Neurosurgery, 1983
- Immunobiology of primary intracranial tumorsJournal of Neurosurgery, 1983
- Réctions d'hypersensibilité retardée avec des lignées de cellules tumorales humaines cultivéesin vitro chez des malades porteurs de tumeurs cérébrales malignesInternational Journal of Cancer, 1972